Skip to content
Newsroom

Policy

The DEA is turning down medical cannabis shops in six states and D.C., and the reasons go straight at state law

After approving more than 900 applicants, the agency has started sending show-cause orders that treat dual licensing and loose certification rules as dealbreakers.

By The Crushed Desk · 6d ago · 5 min read

The DEA is turning down medical cannabis shops in six states and D.C., and the reasons go straight at state law

Photo: Marijuana Moment

The federal registration door that opened for medical cannabis businesses last month is not swinging open for everyone. Marijuana Moment reported on November 11 that the DEA has sent orders to show cause to at least some businesses in California, Delaware, Illinois, North Dakota, Oregon and Washington, D.C. The agency had already turned away applicants in Minnesota, and it earlier approved more than 900 applicants across seven states.

The objections are not about paperwork. Several orders say that states allowing non-medical sales break the Controlled Substances Act's closed-system structure and U.S. treaty obligations. Others take aim at how patients qualify: the agency objects to California letting patients rely on medical-records documentation instead of a written physician certification, to D.C.'s self-certification policy, and to Illinois letting veterans qualify with a year of VA records. In Illinois, the order also questions whether dual medical and recreational licensing has strong enough protections against diversion.

Read together, the orders suggest the DEA is treating its April rescheduling of state-licensed medical cannabis as a narrow medical program, not a general safe harbor for any licensee operating under a state medical label. Businesses in hybrid markets, where the same license holders serve both patients and adult-use customers, look most exposed.

For operators, the practical takeaway is to read your own state's rules the way the DEA will: how patients certify, whether adult-use sales share your license or supply chain, and how product is tracked. A separate DEA warning from last month still stands too, that registrants must source cannabis only from companies that are registered or have applied on time, with that deadline falling in late November. Whether the broader proposal to move non-medical marijuana to Schedule III changes any of this depends on a judge's recommendation, and there is still no date for it.

More from the desk

All stories